Böcker utgivna av Deccan Books

Intelligent classifiers are revolutionizing the field of traffic sign detection, enhancing safety and efficiency on roadways around the world. Traffic signs play a crucial role in guiding drivers, providing important information, and preventing accidents. However, traditional methods of traffic sign detection have often been prone to errors and limitations. This is where intelligent classifiers come into play.Using advanced machine learning techniques, intelligent classifiers have the ability to analyze and interpret vast amounts of data from images and video feeds, enabling them to accurately detect and classify traffic signs in real-time. These classifiers leverage deep neural networks and sophisticated algorithms to recognize patterns, shapes, and colors associated with different types of traffic signs.By harnessing the power of artificial intelligence, intelligent classifiers can overcome challenges such as variations in lighting conditions, occlusions, and complex backgrounds. They can distinguish between different types of signs, including speed limits, stop signs, yield signs, and many others, with high precision and reliability.The benefits of intelligent classifiers in traffic sign detection are manifold. They enhance road safety by ensuring timely and accurate recognition of signs, enabling drivers to respond appropriately. This technology also aids autonomous vehicles in understanding and adhering to traffic regulations. Moreover, intelligent classifiers can assist traffic management systems in monitoring and optimizing traffic flow, reducing congestion, and improving overall transportation efficiency.As research and development in this field continue to progress, intelligent classifiers are poised to become an integral part of smart cities and intelligent transportation systems, providing a robust foundation for safer and more efficient road networks.

To save live of the chronic blood transfusions patients' as much possible through reduce complications of blood transfusion especially multiple blood transfusions and women's having negative blood group.To determine the prevalence of RBCs allo-antibodies in multiple of blood components transfusions.To identify the common alloantibodies in Jaipur.Improving the safety of blood components transfusions.Management & treatment of women having alloantibodies and their fetus.Blood transfusions management of immunized patients.To avoid hemolytic disease of the newborn cases. To decrease the screening and identification antibodies' cost to allow general patients do it regularly.To improve health sociality and reduce of mortality.To help all women having negative blood grouping to made health family.In the recent scientific progress in the field of accurate diagnosis and continues the competition of companies to produce the latest sensitive devices and special solutions for safe blood transfusion, but transfer of blood components and organ transplants frequently remains causes many immediately and delayed problems. Packed R-B-Cs transfer are 100% a valuable to manage health care resource especially for thalassemics, case of myeloproliferative disorders, hematological disorders, end stage renal failure, sufferer of leukemia and anemia, cancer, and organs transplant case as liver, as well as Kidney and bone marrow. Chronic packed red cells transfer can cause unwanted more complex complications called acute or/and chronic blood- transfusion reactions in a patient that may be cause to death in some cases. Development of allo-antibodies to vary R-B-Cs antigens is very an important immune intermediated delayed hemolytid transfusion reaction (DHTR) that may be causing death in most case especially in children, or old illness. It is a matter of major concern about of multi-transfused cases and in women who had multiple pregnancies.'Allo-immunization to R-B-Cs antigen is one of the major complexities regular of the blood components transfused, particularly in sufferer who are chronically transfusions through his/her life. The elements for allo-immunization are complex and involve three major contributing factors: the R-B-Cs antigen asymmetry between the donor and the recipient, the receiver immune situation, and the Immuno-modulatory impact of the allogenic blood components transfusions on the recipient's immune system. Multiple ethnicity of the population has caused genetic heterogeneity among the population which in turn led to a wide variation of antibody specificity among the population.

The brain, administrator of the whole body is a delicate and soft organ of the body thatcontrols and regulates most of our abilities to think, see, feel, hear, and much more. Theadministrator has very tight security unlike other organs called the blood-brain barrier(BBB) which allows only limited things to enter the brain. The protection (BBB) is fullof a series of defences that helps to protect the brain from most of the internal andexternal threats. The presence of these protections, most importantly BBB, also offersdifficulties to treat any disease condition in the brain. But, the advancement inneuroscience and drug delivery research has accorded many possible ways to bypass,open, or cross this barrier to treat brain diseases effectively including cancer.BBB is provided with a layer of endothelial cells which also cover the outer layer of allother organs and blood vessels in the body. Generally, this endothelial cell layer hasgaps to allow passage of different important materials including nutrients andmedicines through the layer. But, in the case of brain, these gaps are covered andblocked with proteins that restrict and controls the passage of materials through thelayer. For example, necessary items like glucose, insulin and oxygen are allowed whiletoxins, bacteria and most of medicines are not allowed.Brain cancer is a rapidly expanding disease affecting a large population and is the 10thdominant cause of mortality. The survival rate for brain cancerpatients after starting the treatment with radiation and chemotherapy is less than a year. Treatment of brain cancer with chemotherapeutics is very limited due to the presence of BBB and therefore their restricted entry to the brain. Strategiesacquired to deliver chemotherapeutic drugs to brain include both invasive and noninvasivetechniques. Invasive technique includes chemical or osmotic opening of BBB whilenon-invasive technique includes enhanced transcellular transport by modifying the drugto increase their lipid solubility, inhibition of efflux transporters, use of chimericpeptides, trojan horse approach, intranasal delivery and use of transport or carriersystems.The non-invasive carrier system-based strategy utilises delivery of drugs to braintumors using nano-sized particle systems and this strategy found to have significantpotential in improved therapy of brain disorders. Nanoparticle delivery systems cancamouflage their cargoes to the brain and can provide sustained release of therapeuticmolecules inside the brain resulting in a longer half-life, protection againstenvironmental conditions, and reduced toxicities. Studies comprising direct as well asintravenous administration of nanoparticles loaded with therapeutic agents into thebrain have shown promise in the treatment of brain cancers. But, complex synthesis procedures, low biocompatibility andbiodegradability, and toxicity problems of nanoparticle delivery systems have raisedconcerns for their clinical development.